Genome Editing Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast 2024-2028

Genome Editing Market Size 2024-2028

The global genome editing market size is estimated to grow by USD 7.23 billion, at a CAGR of 15.88% between 2023 and 2028. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

Moreover, technological progress has revolutionized genome editing, introducing precise tools like CRISPR-Cas9, TALENs, and ZFNs. These advancements allow targeted modifications with unprecedented accuracy, enabling diverse research and therapeutic possibilities. Techniques like base and epigenome editing extend capabilities, facilitating nuanced genetic alterations. High-throughput screening methods expedite gene function discovery and drug target identification. Automation enhances workflow efficiency, while bioinformatics tools optimize protocols and safety assessments. These advancements drive the growth of the market by enabling efficient research and therapeutic development.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by End-user, Delivery Mode, and Geography Analysis

Genome editing utilizes cutting-edge technologies like CRISPR genome editing technology to precisely modify genetic material within an organism. It targets specific genetic anomalies such as single nucleotide polymorphisms (SNPs) associated with conditions like cystic fibrosis (CF) and tumor development. The application of gene editing techniques like SMR and Pro-code holds promise for addressing genetic disorders and advancing scientific research. Modification of a single gene in an organism can result in genetic abnormalities, leading to conditions such as sickle cell disease, Parkinson's disease, and hearing loss.

End-user Analysis

The market share growth by the pharmaceutical and biotechnology companies segment will be significant during the forecast period. Genome empowers researchers to explore gene function and disease mechanisms, aiding in drug discovery and personalized medicine. By creating genetic mutations in target genes, scientists uncover insights into disease biology and drug responses.

Get a glance at the market contribution of various segments Download PDF Sample

The pharmaceutical and biotechnology companies segment was valued at USD 1.86 billion in 2018. Genome-edited models assist in preclinical drug screening and personalized therapy development, enhancing treatment outcomes. CRISPR/Cas9 technology revolutionizes genetic engineering, offering versatile applications in therapy development and research. Pharmaceutical and biotech firms increasingly leverage gene editing tools for drug discovery, viral vector production, driving market growth during the forecast period. 

Delivery Mode Analysis

Ex-vivo segment holds promise for treating genetic disorders, cancer, and infectious diseases, driving demand for therapies targeting specific mutations and enhancing treatment efficacy. It enables tailored cellular therapies and personalized medicine by modifying patient-derived cells ex vivo based on individual genetic and disease profiles. Ex-vivo editing also aids in developing cell-based therapies and plays a role in basic research, drug discovery, and biotechnology. Vertex Pharmaceuticals' recent licensing deal with Editas Medicine underscores the potential of ex-vivo editing in advancing scientific research and commercial opportunities, fueling growth in the market during the forecast period. 

In-vivo segment offers promising prospects for treating genetic disorders and inherited conditions, tailoring precision medicine to individual patients. Demand is rising for personalized therapies using in-vivo editing to target disease-causing genes. It's crucial in gene therapy, delivering therapeutic genes directly into patients' bodies. In-vivo editing also shows potential in cancer treatment by modifying cancer cells and enhancing immune responses. Moreover, it's valuable in basic research and agriculture, driving growth in the market during the forecast period. 

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America is home to a thriving biopharmaceutical and biotechnology sector, comprising pharmaceutical companies, biotech startups, CROs, and academic research institutions. These organizations leverage genome technologies for drug discovery, target validation, preclinical research, and therapeutic development, driving the demand for genome tools, services, and expertise.

Additionally, government funding agencies, private investors, and venture capital firms in North America provide substantial financial support for genome research, development, and commercialization efforts. The availability of research grants, funding opportunities, and investment capital fuels innovation and accelerates the translation of such technologies into practical applications, driving regional market expansion. Thus, these factors will drive the growth of the regional market during the forecast period.

Buy the Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

• AstraZeneca PLC: The company provides genome editing, which is a fundamental component of functional genomics and enables the deletion or alteration of genes in cells in order to understand their functional role in disease. CRISPR is one of the most widely used genome editing tools.

Caribou Biosciences Inc., Cellectis SA, Cibus, Danaher Corp., Editas Medicine Inc., Egenesis, GenScript Biotech Corp., Horizon Discovery Ltd., Intellia Therapeutics Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs Inc., OriGene Technologies Inc., PerkinElmer Inc, Precision BioSciences Inc., Sangamo Therapeutics Inc., Takara Bio Inc., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market is witnessing significant advancements in modification techniques, enabling precise alterations in DNA strands of various organisms. Technologies like Zinc finger nucleases (ZFNs) are revolutionizing treatment approaches for genetic abnormalities such as sickle cell disease, Parkinson’s disease, and hearing loss. Additionally, the field extends to genetically modified crops and therapeutic interventions for conditions like cystic fibrosis, hemophilia, and breast cancer, fostering extensive clinical trials and research in molecular biology. This transformative innovation holds promise in combating diseases and enhancing agricultural yields. Further, the market is propelled by advancements like gene-editing technologies, targeting single gene modifications in various organisms. This technology shows promise in addressing genetic conditions such as cystic fibrosis, multiple myeloma, and even enhancing traits in organisms like white button mushrooms. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Drivers

Increasing demand for personalized medicine is the key factor driving the market. Personalized medicine tailors medical treatment to individual patient characteristics, including genetics and lifestyle. Genome editing allows precise genome manipulation to correct mutations and develop targeted therapies. With rising demand for precision therapeutics, genome editing becomes essential for personalized treatment strategies. It offers targeted therapies for genetic disorders, including rare diseases, by correcting disease-causing mutations.

Moreover, genome editing also aids in gene and cell-based therapies, like CAR-T cells, tailored to patients' genetic profiles. These therapies promise improved outcomes and reduced side effects compared to conventional treatments. Additionally, genome editing contributes to pharmacogenomics, optimizing drug selection and dosage based on genetic variations. Thus, the growing demand for personalized medicine drives the market growth during the forecast period. 

Significant Trends

Growing integration with AI and data analytics is one of the primary market trends. AI and data analytics play a crucial role in optimizing genome editing strategies by analyzing vast datasets, predicting editing outcomes, and identifying ideal target sites. Machine learning algorithms refine editing protocols, enhance efficiency, and minimize off-target effects by learning from experimental data. Predictive modeling and simulation-driven by AI simulate genome editing processes, predict outcomes, and evaluate editing interventions' potential impacts. These computational models offer insights into editing kinetics, DNA repair mechanisms, and cellular responses, guiding experimental design.

Additionally, AI algorithms predict and mitigate off-target effects by analyzing genomic and epigenetic features, enhancing specificity and safety in therapeutic applications. AI-powered automation and high-throughput screening platforms streamline workflows, enabling rapid experimentation and data analysis. Integrated AI systems automate procedures, accelerating research throughput and enabling the discovery of novel therapeutic candidates. Therefore, such factors will drive market growth during the forecast period. 

Major Challenges

Concerns associated with off-target effects is the major challenge that affects the market expansion. Off-target effects present significant challenges in genome editing by causing unintended genetic modifications at genomic loci apart from the target site. These unintended changes can disrupt normal gene function, affecting cellular behavior and posing safety risks, particularly in therapeutic applications. Off-target effects reduce editing specificity and efficacy, compromising research reliability and therapeutic outcomes.

Furthermore, off-target effects also elevate the risk of adverse events like genotoxicity and unintended phenotypic changes, potentially affecting cell viability and clinical trial outcomes. Moreover, addressing off-target concerns is crucial for gaining regulatory approval and commercializing genome editing products, necessitating rigorous preclinical and clinical validation studies. Hence, off-target effects hinder market growth during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market forecasting includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• End-user Outlook
  • Pharmaceutical and biotechnology companies
  • Academic institutes and research laboratories
  • CRO

• Delivery Mode Outlook
  • Ex-viv
  • In-vivo

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Argentina
    • Australia
    • Brazil

Market Analyst Overview:

The market is experiencing rapid growth, driven by advancements in gene-edited therapies and genetic manipulation techniques. Companies like Arcturus Therapeutics and Beam Therapeutics are pioneering innovative approaches in gene editing services and prime editing, offering new avenues for treating genetic diseases. With a focus on regenerative medicine and cell and gene therapies, the market is witnessing significant interest in clinical trial pipeline development and drug development for conditions such as peripheral artery disease and spinal muscular atrophy. Furthermore, genome editing technologies like TALEN are revolutionizing gene delivery and cell line engineering, promising breakthroughs in addressing various autoimmune diseases and liver cancer and stomach cancer. Genome editing and synthetic biology are closely related fields, with genome editing techniques such as CRISPR enabling precise modifications of genetic material, which can be harnessed to advance synthetic biology applications for creating novel organisms and biological systems

Moreover, the market is witnessing exponential growth, driven by advancements in TALEN gene-editing technology and gene and stem cell therapy. Innovations like UCART123 offer promising treatments for R/R acute myeloid leukemia and other human genetic diseases. Moreover, the market is benefiting from the application of genome editing in prophylaxis treatment and animal breeding, revolutionizing agriculture with GM seeds such as corn, soybean, cotton, sugar beets, and canola. Additionally, genome editing plays a crucial role in combating diseases like lung cancer, rectum and colon cancer, through the manipulation of DNA-binding proteins and enzyme like polyphenol oxidase (PPO). This market's evolution underscores its potential to reshape healthcare and agriculture, with botanists and agriculturists at the forefront of innovation.

Download the Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch